Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpNew England Journal of Medicine
• journal#1
Rebecca L Haffajee, Richard G Frank
No abstract text is available yet for this article.
January 8, 2020: New England Journal of Medicine
#2
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, Jean-Claude Tardif, Seth J Baum, Elizabeth Steinhagen-Thiessen, Michael D Shapiro, Erik S Stroes, Patrick M Moriarty, Børge G Nordestgaard, Shuting Xia, Jonathan Guerriero, Nicholas J Viney, Louis O'Dea, Joseph L Witztum
BACKGROUND: Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter)...
January 1, 2020: New England Journal of Medicine
#3
Nicholas Bagley
No abstract text is available yet for this article.
January 1, 2020: New England Journal of Medicine
#4
(no author information available yet)
No abstract text is available yet for this article.
December 27, 2019: New England Journal of Medicine
#5
LETTER
Jitender Jinagal, Poonam Dhiman
No abstract text is available yet for this article.
December 23, 2019: New England Journal of Medicine
#6
Kathleen P Hartnett, Aaron Kite-Powell, Megan T Patel, Brittani L Haag, Michael J Sheppard, Taylor P Dias, Brian A King, Paul C Melstrom, Matthew D Ritchey, Zachary Stein, Nimi Idaikkadar, Alana M Vivolo-Kantor, Dale A Rose, Peter A Briss, Jennifer E Layden, Loren Rodgers, Jennifer Adjemian
No abstract text is available yet for this article.
December 20, 2019: New England Journal of Medicine
#7
Benjamin C Blount, Mateusz P Karwowski, Peter G Shields, Maria Morel-Espinosa, Liza Valentin-Blasini, Michael Gardner, Martha Braselton, Christina R Brosius, Kevin T Caron, David Chambers, Joseph Corstvet, Elizabeth Cowan, Víctor R De Jesús, Paul Espinosa, Carolina Fernandez, Cory Holder, Zsuzsanna Kuklenyik, Jennifer D Kusovschi, Cody Newman, Gregory B Reis, Jon Rees, Chris Reese, Lalith Silva, Tiffany Seyler, Min-Ae Song, Connie Sosnoff, C R Spitzer, Denise Tevis, Lanqing Wang, Cliff Watson, Mark D Wewers, Baoyun Xia, Douglas T Heitkemper, Isaac Ghinai, Jennifer Layden, Peter Briss, Brian A King, Lisa J Delaney, Christopher M Jones, Grant T Baldwin, Anita Patel, Dana Meaney-Delman, Dale Rose, Vikram Krishnasamy, John R Barr, Jerry Thomas, James L Pirkle
BACKGROUND: The causative agents for the current national outbreak of electronic-cigarette, or vaping, product use-associated lung injury (EVALI) have not been established. Detection of toxicants in bronchoalveolar-lavage (BAL) fluid from patients with EVALI can provide direct information on exposure within the lung. METHODS: BAL fluids were collected from 51 patients with EVALI in 16 states and from 99 healthy participants who were part of an ongoing study of smoking involving nonsmokers, exclusive users of e-cigarettes or vaping products, and exclusive cigarette smokers that was initiated in 2015...
December 20, 2019: New England Journal of Medicine
#8
EDITORIAL
Jane E Salmon, Timothy B Niewold
No abstract text is available yet for this article.
December 18, 2019: New England Journal of Medicine
#9
Eric F Morand, Richard Furie, Yoshiya Tanaka, Ian N Bruce, Anca D Askanase, Christophe Richez, Sang-Cheol Bae, Philip Z Brohawn, Lilia Pineda, Anna Berglind, Raj Tummala
BACKGROUND: Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end point from that trial as the primary end point. METHODS: We randomly assigned patients in a 1:1 ratio to receive intravenous anifrolumab (300 mg) or placebo every 4 weeks for 48 weeks...
December 18, 2019: New England Journal of Medicine
#10
EDITORIAL
Thomas H Lee, Namita Seth Mohta, Edward Prewitt, Edward W Campion, Stephen Morrissey, Jeffrey M Drazen, Eric J Rubin
New England Journal of Medicine, Volume 382, Issue 1, Page 80-81, January 2020.
December 16, 2019: New England Journal of Medicine
#11
Dennis J Slamon, Patrick Neven, Stephen Chia, Peter A Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia Val Bianchi, Francisco J Esteva, Miguel Martín, Arnd Nusch, Gabe S Sonke, Luis De la Cruz-Merino, J Thaddeus Beck, Xavier Pivot, Manu Sondhi, Yingbo Wang, Arunava Chakravartty, Karen Rodriguez-Lorenc, Tetiana Taran, Guy Jerusalem
BACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Here we report the results of a protocol-specified second interim analysis of overall survival. METHODS: Patients were randomly assigned in a 2:1 ratio to receive either ribociclib or placebo in addition to fulvestrant as first-line or second-line treatment...
December 11, 2019: New England Journal of Medicine
#12
Adit A Ginde, Roy G Brower, Jeffrey M Caterino, Lani Finck, Valerie M Banner-Goodspeed, Colin K Grissom, Douglas Hayden, Catherine L Hough, Robert C Hyzy, Akram Khan, Joseph E Levitt, Pauline K Park, Nancy Ringwood, Emanuel P Rivers, Wesley H Self, Nathan I Shapiro, B Taylor Thompson, Donald M Yealy, Daniel Talmor
BACKGROUND: Vitamin D deficiency is a common, potentially reversible contributor to morbidity and mortality among critically ill patients. The potential benefits of vitamin D supplementation in acute critical illness require further study. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D3 supplementation in critically ill, vitamin D-deficient patients who were at high risk for death. Randomization occurred within 12 hours after the decision to admit the patient to an intensive care unit...
December 11, 2019: New England Journal of Medicine
#13
James H Dunk, David S Jones
No abstract text is available yet for this article.
December 11, 2019: New England Journal of Medicine
#14
Rashmi K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A Hurvitz, Nancy U Lin, Virginia Borges, Vandana Abramson, Carey Anders, Philippe L Bedard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit S Shachar, Volkmar Müller, Sofia Braga, Francois P Duhoux, Richard Greil, David Cameron, Lisa A Carey, Giuseppe Curigliano, Karen Gelmon, Gabriel Hortobagyi, Ian Krop, Sibylle Loibl, Mark Pegram, Dennis Slamon, M Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P Winer
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine...
December 11, 2019: New England Journal of Medicine
#15
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock-Ah Im, Keun Seok Lee, Sara A Hurvitz, Javier Cortes, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian Krop
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation...
December 11, 2019: New England Journal of Medicine
#16
Philip J Landrigan, Howard Frumkin, Brita E Lundberg
No abstract text is available yet for this article.
December 4, 2019: New England Journal of Medicine
#17
Scott Burris, Evan D Anderson, Corey S Davis, Leo Beletsky
New England Journal of Medicine, Volume 382, Issue 1, Page 4-5, January 2020.
December 4, 2019: New England Journal of Medicine
#18
Sabue Mulangu, Lori E Dodd, Richard T Davey, Olivier Tshiani Mbaya, Michael Proschan, Daniel Mukadi, Mariano Lusakibanza Manzo, Didier Nzolo, Antoine Tshomba Oloma, Augustin Ibanda, Rosine Ali, Sinaré Coulibaly, Adam C Levine, Rebecca Grais, Janet Diaz, H Clifford Lane, Jean-Jacques Muyembe-Tamfum, Billy Sivahera, Modet Camara, Richard Kojan, Robert Walker, Bonnie Dighero-Kemp, Huyen Cao, Philippe Mukumbayi, Placide Mbala-Kingebeni, Steve Ahuka, Sarah Albert, Tyler Bonnett, Ian Crozier, Michael Duvenhage, Calvin Proffitt, Marc Teitelbaum, Thomas Moench, Jamila Aboulhab, Kevin Barrett, Kelly Cahill, Katherine Cone, Risa Eckes, Lisa Hensley, Betsey Herpin, Elizabeth Higgs, Julie Ledgerwood, Jerome Pierson, Mary Smolskis, Ydrissa Sow, John Tierney, Sumathi Sivapalasingam, Wendy Holman, Nikki Gettinger, David Vallée, Jacqueline Nordwall
BACKGROUND: Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial. METHODS: We conducted a trial of four investigational therapies for EVD in the Democratic Republic of Congo, where an outbreak began in August 2018. Patients of any age who had a positive result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay were enrolled...
November 27, 2019: New England Journal of Medicine
#19
EDITORIAL
Myron M Levine
New England Journal of Medicine, Volume 381, Issue 24, Page 2365-2366, December 2019.
November 27, 2019: New England Journal of Medicine
#20
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng-Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean-Charles Soria
BACKGROUND: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). The trial showed longer progression-free survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0...
November 21, 2019: New England Journal of Medicine
Fetching more papers... 
